MPI and Mundipharma EDO GmbH enters agreement of DRP(TM) for their anti cancer lead compound EDO-S101 in clinical trials

HORSHOLM, Denmark, Dec. 7, 2015 (GLOBE NEWSWIRE) — Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI and Mundipharma EDO GmbH have entered into an agreement for the development and testing of a DRP(TM) biomarker for Mundipharma EDO’s lead compound EDO-S101 for the treatment of cancer.EDO-S101 is a first in class fusion molecule that combines two drugs’ mechanism of action in the cancer cell in order to increase the effect of treatment.MPI’s specific DRPTM multiple biomarker for EDO-S101 is to identify those patients who have the highest likelihood of response to the combination of bendamustine and vorinostat. Thereby the response rate will increase and time and resources spent will decrease.“We are excited at the prospect of our partner Mundipharma EDO moving into Phase I with a DRP(TM) biomarker developed by MPI A/S,” says adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI. “This is precisely where MPI’s DRPTM makes a difference, due to the fact that our technology can be used for all cancer diseases and for most anti cancer drugs on the market or under development,” adds adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI.